QUTENZA + Lidocaine + Tramadol
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
or Peripheral Nerve Injury (PNI)
Conditions
or Peripheral Nerve Injury (PNI), Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN)
Trial Timeline
Jul 6, 2011 → Apr 25, 2012
NCT ID
NCT01416116About QUTENZA + Lidocaine + Tramadol
QUTENZA + Lidocaine + Tramadol is a approved stage product being developed by Astellas Pharma for or Peripheral Nerve Injury (PNI). The current trial status is completed. This product is registered under clinical trial identifier NCT01416116. Target conditions include or Peripheral Nerve Injury (PNI), Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01416116 | Approved | Completed |
Competing Products
20 competing products in or Peripheral Nerve Injury (PNI)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SON-080 | Sonnet BioTherapeutics | Phase 1/2 | 36 |
| LY3857210 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg | Yuhan | Approved | 85 |
| YHD1119 + Lyrica | Yuhan | Phase 1 | 33 |
| Anplag Tab. 100mg bid + Anplag Tab. 100mg tid | Yuhan | Approved | 85 |
| YHD1119 + Lyrica | Yuhan | Phase 1 | 33 |
| YHD1119 + Lyrica | Yuhan | Phase 3 | 77 |
| YHD1119 300mg + YHD1119 300mg | Yuhan | Phase 1 | 33 |
| DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsule | Daiichi Sankyo | Phase 2 | 52 |
| edoxaban + Clopidogrel + Aspirin | Daiichi Sankyo | Phase 2 | 52 |
| DS-5565 + placebo | Daiichi Sankyo | Phase 3 | 77 |
| Mirogabalin + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| DS-5565 | Daiichi Sankyo | Phase 3 | 77 |
| Valemetostat Tosylate | Daiichi Sankyo | Phase 2 | 52 |
| ASP3662 + pregabalin + ASP3662 placebo + pregabalin placebo | Astellas Pharma | Phase 2 | 52 |
| Qutenza | Astellas Pharma | Pre-clinical | 23 |
| Qutenza exposure | Astellas Pharma | Pre-clinical | 23 |
| QUTENZA | Astellas Pharma | Phase 3 | 77 |
| Qutenza + Pregabalin | Astellas Pharma | Approved | 85 |
| Capsaicin 8% + Placebo | Astellas Pharma | Phase 3 | 77 |